Population Genomics Driving Precision Health: Singapore’s National Precision Medicine Programme

4 March 2021

Hear about Singapore’s National Precision Medicine Strategy from Dr Tai E Shyong, Chief Medical Officer of Precision Health Research, Singapore (PRECISE), and how Singapore seeks to address the challenges in the clinical implementation of precision medicine approaches and technologies.


Singapore’s National Precision Medicine Programme – Pathways to Clinical Implementation and Value Demonstration


4 March 2021


11:35am – 12 noon (SGT)


Singapore’s national precision medicine program will complement other precision medicine efforts by adding genotypic and phenotypic diversity. These data can then be used to improve diagnosis, predict disease, identify novel therapeutic targets or tailor therapy to improve outcomes and minimise side effects.

Oncology is perhaps one area where targeted therapies have been adopted relatively frequently. However, beyond Oncology, the impact of precision medicine on population health has been limited by a paucity of clinical pathways incorporating genomic technologies that have been implemented at scale.

Widespread adoption has been limited by at least two factors:

  • inaccessibility to skillsets and services within the healthcare systems to deploy these technologies at scale; and
  • uncertainty regarding the impact of implementation on disease outcomes, and healthcare costs.

To address this, the national precision medicine programme in Singapore includes efforts to:

  • identify disease areas where genomic technologies could potentially add value;
  • identify gaps in regulations, services and skills that limit adoption of genomics technologies in public health institutions and support institutions in filling these gaps;
  • conduct clinical implementation pilots in disease areas that incorporate early health technology assessment to optimise the cost and cost-effectiveness of these programmes.


Prof Tai E Shyong, Chief Medical Officer, PRECISE